Xcout IntelBioxodes
Bioxodes is a Belgian clinical-stage biotechnology company founded in 2013 and located in Gosselies. The firm focuses on developing breakthrough treatments for hemorrhagic stroke patients.
Subscribe to see Bioxodes’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Bioxodes at a glance
Bioxodes is a biotechnology company headquartered in Belgium. Its most recent funding round, Series A, raised $5.5M in December 2025. Xcout tracks 9 named people at Bioxodes, including Didier Le Normand (Chief Financial Officer, Consultant).
Bioxodes leadership
- Didier Le NormandChief Financial Officer, Consultant
- Hans WarrinnierChief Medical Officer
- Marc DechampsManaging Director
- Tomas ComblainHead of Finance
- Philippe MonteyneChairman
- Marc DechampsManaging Director
3 more named people on record for Bioxodes, with roles, board committees and tenure — see the full roster →
Bioxodes funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $5.5M | 1 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
Bioxodes competitors
A few of Bioxodes's closest competitors — see the full list of competitors and alternatives →
EPICS Therapeutics is a clinical-stage biotechnology company headquartered in Gosselies, Belgium, dedicated to drug discovery and development for small molecule drugs. The company pioneers targeted therapies focusing on RNA epigenetic regulation to transform cancer treatment.
Vaderis Therapeutics AG is a clinical-stage biotechnology company focused on developing novel treatments for severe vascular diseases. The company is headquartered in Basel, Switzerland.
HemostOD is a preclinical-stage biotech company based in Lausanne, Switzerland, pioneering the ex vivo manufacturing of donor-free, off-the-shelf universal human blood platelets to save lives.
Acticor Biotech is a clinical-stage biopharmaceutical company headquartered in Paris, France, that specializes in developing innovative treatments for acute thrombotic diseases.
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Get Bioxodes's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Bioxodes in Xcout Intel
- 9 named people with titles, LinkedIn and board committees
- 1 funding round with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access